DiaSorin offers the diabetes line, on the RIA format and LIAISON® systems.
The LIAISON® Insulin assay uses chemiluminescent immunoassay (CLIA) technology for the in vitro quantitative determination of insulin in human serum or EDTA-plasma specimens. The test has to be performed on the LIAISON® Analyzer.
In vitro assay for the quantitative determination of C-peptide in human serum, heparinised or citrated plasma, and urine. The test has to be performed on the LIAISON® Analyzer family.
Diabetes is the sixth leading cause of death, and the fifth leading cause of death from disease in the world. US estimations indicate that diabetes costs many billion dollars annually in direct medical costs as well as in indirect costs (loss of work, disability, loss of life). Evaluation of the diabetic's status using major parameter such us Insulin and C-Peptide is critical to correctly diagnose and manage this condition.